Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1) dysregulation has been observed in several cancers including acute lymphocytic leukemia (ALL), breast, hepatocellular, and colorectal [32]. This evidence concerns the gene UBE2Q1 and acute lymphoblastic leukemia.